These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 11341102)

  • 1. Antioxidants suppress mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE).
    Suwannaroj S; Lagoo A; Keisler D; McMurray RW
    Lupus; 2001; 10(4):258-65. PubMed ID: 11341102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus.
    McMurray RW; Elbourne KB; Lagoo A; Lal S
    J Rheumatol; 1998 Dec; 25(12):2364-70. PubMed ID: 9858431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of renal disease and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE) by chenodeoxycholic acid.
    Suwannaroj S; Lagoo A; McMurray RW
    Lupus; 2001; 10(8):562-7. PubMed ID: 11530998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble human CD83 ameliorates lupus in NZB/W F1 mice.
    Starke C; Steinkasserer A; Voll RE; Zinser E
    Immunobiology; 2013 Nov; 218(11):1411-5. PubMed ID: 23886695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulatory effects of H.P. Acthar Gel on B cell development in the NZB/W F1 mouse model of systemic lupus erythematosus.
    Decker DA; Grant C; Oh L; Becker PM; Young D; Jordan S
    Lupus; 2014 Jul; 23(8):802-12. PubMed ID: 24759631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of estrogen and prolactin on autoimmune disease in the NZB/NZW F1 mouse model of systemic lupus erythematosus.
    Elbourne KB; Keisler D; McMurray RW
    Lupus; 1998; 7(6):420-7. PubMed ID: 9736327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-21 receptor blockade inhibits secondary humoral responses and halts the progression of preestablished disease in the (NZB × NZW)F1 systemic lupus erythematosus model.
    Zhang M; Yu G; Chan B; Pearson JT; Rathanaswami P; Delaney J; Ching Lim A; Babcook J; Hsu H; Gavin MA
    Arthritis Rheumatol; 2015 Oct; 67(10):2723-31. PubMed ID: 26097207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decrease in glomerulonephritis and Th1-associated autoantibody production after progesterone treatment in NZB/NZW mice.
    Hughes GC; Martin D; Zhang K; Hudkins KL; Alpers CE; Clark EA; Elkon KB
    Arthritis Rheum; 2009 Jun; 60(6):1775-84. PubMed ID: 19479860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse.
    Werwitzke S; Trick D; Kamino K; Matthias T; Kniesch K; Schlegelberger B; Schmidt RE; Witte T
    Arthritis Rheum; 2005 Nov; 52(11):3629-38. PubMed ID: 16255055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated deaths from systemic lupus erythematosus in NZB x NZW F1 mice treated with the testosterone-blocking drug flutamide.
    Walker SE; Besch-Williford CL; Keisler DH
    J Lab Clin Med; 1994 Sep; 124(3):401-7. PubMed ID: 8083583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
    Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
    Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ongoing immunologic activity after short courses of pulse cyclophosphamide in the NZB/W murine model of systemic lupus erythematosus.
    Austin HA; Patel AD; Cadena CA; Boumpas DT; Balow JE
    J Rheumatol; 1997 Jan; 24(1):61-8. PubMed ID: 9002012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCR3 promotes the production of IgG1 autoantibodies but is not essential for the development of lupus nephritis in NZB/NZW mice.
    Moser K; Kalies K; Szyska M; Humrich JY; Amann K; Manz RA
    Arthritis Rheum; 2012 Apr; 64(4):1237-46. PubMed ID: 22006377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus.
    Zoja C; Casiraghi F; Conti S; Corna D; Rottoli D; Cavinato RA; Remuzzi G; Benigni A
    Arthritis Rheum; 2007 May; 56(5):1629-37. PubMed ID: 17469145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defects in the regulation of anti-DNA antibody production in aged lupus-prone (NZB x NZW)F1 mice: analysis of T-cell lymphokine synthesis.
    Sato MN; Minoprio P; Avrameas S; Ternynck T
    Immunology; 1995 May; 85(1):26-32. PubMed ID: 7635519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone.
    Macanovic M; Sinicropi D; Shak S; Baughman S; Thiru S; Lachmann PJ
    Clin Exp Immunol; 1996 Nov; 106(2):243-52. PubMed ID: 8918569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Animal models utilized in the research of autoimmune disease control: experimental therapy of glomerulonephritis in NZB/W F1 mice.
    Okudaira H; Terada E; Okudaira K
    Prog Clin Biol Res; 1987; 229():157-74. PubMed ID: 3601985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raloxifene modulates estrogen-mediated B cell autoreactivity in NZB/W F1 mice.
    Zhang Y; Saha S; Rosenfeld G; Gonzalez J; Pepeljugoski KP; Peeva E
    J Rheumatol; 2010 Aug; 37(8):1646-57. PubMed ID: 20551107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppression With Mycophenolate Mofetil Attenuates Hypertension in an Experimental Model of Autoimmune Disease.
    Taylor EB; Ryan MJ
    J Am Heart Assoc; 2017 Feb; 6(3):. PubMed ID: 28242635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class-specific regulation of anti-DNA antibody synthesis and the age-associated changes in (NZB x NZW)F1 hybrid mice.
    Sekigawa I; Okada T; Noguchi K; Ueda G; Hirose S; Sato H; Shirai T
    J Immunol; 1987 May; 138(9):2890-5. PubMed ID: 2952727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.